Chronic opioid pain treatment converted to buprenorphine: A case series using a 3-step low-dose incremental dosing guideline

Gregory Acampora; Yi Zhang

doi:10.5055/jom.0822

Authors

Gregory Acampora, MD https://orcid.org/0000-0001-8873-8453
Yi Zhang, MD, PhD https://orcid.org/0000-0002-4081-5146

DOI:

https://doi.org/10.5055/jom.0822

Keywords:

full agonist opioid, treatment for pain, buprenorphine, management of chronic pain

Abstract

We report a 30-case series from the Pain Management Center at the Massachusetts General Hospital where we have applied a guideline to convert chronic treatment for pain from full agonist opioids (FAO) to buprenorphine (BUP). Of the patients, 24 (80 percent) elected to continue BUP over FAO. Five conversions were stopped for side effects (fatigue) and/or lack of sufficient pain reduction. One patient elected not to participate on the day that the conversion was to begin. There were no major adverse events. We conclude that conversion to BUP should be considered as an alternative to treat patients on chronic opioids for pain.

Author Biographies

Gregory Acampora, MD

Assistant Professor Harvard Medical School, Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

Yi Zhang, MD, PhD

Associate Professor Harvard Medical School, Anesthesiology, Massachusetts General Hospital, Boston, Massachusetts

References

CMS Government: HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Available at cms.gov. Accessed October 1, 2023.

Dalal S, Chitneni A, Berger AA, et al.: Buprenorphine for chronic pain: A safer alternative to traditional opioids. Health Psychol Res. 2021; 9(1): 27241. DOI: 10.52965/001c.27241. DOI: https://doi.org/10.52965/001c.27241

Acampora GA, Nisavic M, Zhang Y: Perioperative buprenorphine continuous maintenance and administration simultaneous with full opioid agonist: Patient priority at the interface between medical disciplines. J Clin Psychiatry. 2020; 81(1). DOI: 10.4088/JCP.19com12810. DOI: https://doi.org/10.4088/JCP.19com12810

Quaye A, Potter K, Roth S, et al.: Perioperative continuation of buprenorphine at low-moderate doses was associated with lower postoperative pain scores and decreased outpatient opioid dispensing compared with buprenorphine discontinuation. Pain Med. 2020; 21(9): 1955-1960. DOI: 10.1093/pm/pnaa020. DOI: https://doi.org/10.1093/pm/pnaa020

Hämmig R, Kemter A, Strasser J, et al.: Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method. Subst Abuse Rehabil. 2016; 7: 99-105. DOI: 10.2147/SAR.S109919. DOI: https://doi.org/10.2147/SAR.S109919

Tara A, Acampora G, Wang J, et al.: Facilitating discontinuation of intravenous opioids by – concurrent use of sublingual buprenorphine with rapid microdosing – induction: A pain management case study. J Opioid Manag. 2021; 17(7): 153-158. DOI: 10.5055/jom.2021.0652. DOI: https://doi.org/10.5055/jom.2021.0652

Berna C, Kulich RJ, Rathmell JP: Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo Clin Proc. 2015; 90(6): 828-842. DOI: 10.1016/j.mayocp.2015.04.003. DOI: https://doi.org/10.1016/j.mayocp.2015.04.003

Sandbrink F, Murphy JL, Johansson M, et al.: The use of opioids in the management of chronic pain: Synopsis of the 2022 updated US Department of veterans affairs and US Department of defense clinical practice guideline. Ann Intern Med. 2023; 176(3): 388-397. DOI: 10.7326/M22-2917. DOI: https://doi.org/10.7326/P22-0030

Kumar R, Viswanath O, Saadabadi A: Buprenorphine. In StatPearls. Treasure Island, FL: StatPearls Publishing, 2023.

SAMHSA: Waiver Elimination (MAT Act). Available at https://www.samhsa.gov/medications-substance-use-disorders/waiverelimination-mat-act. Accessed October 1, 2023.

Gudin J, Fudin J: A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther. 2020; 9(1): 41-54. DOI: 10.1007/s40122-019-00143-6. DOI: https://doi.org/10.1007/s40122-019-00143-6

Gurevich VV, Gurevich EV: GPCR signaling regulation: The role of GRKs and arrestins. Front Pharmacol. 2019; 10: 125. DOI: 10.3389/fphar.2019.00125. DOI: https://doi.org/10.3389/fphar.2019.00125

Peterson YK, Luttrell LM: The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharmacol Rev. 2017; 69(3): 256-297. DOI: 10.1124/pr.116.013367. DOI: https://doi.org/10.1124/pr.116.013367

Williams JT, Ingram SL, Henderson G, et al.: Regulation of μ-opioid receptors: Desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013; 65(1): 223-254. DOI: 10.1124/pr.112.005942. DOI: https://doi.org/10.1124/pr.112.005942

Greenwald MK, Herring AA, Perrone J, et al.: A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med. 2022; 80(6): 509-524. DOI: 10.1016/j.annemergmed.2022.05.032. DOI: https://doi.org/10.1016/j.annemergmed.2022.05.032